Cangrelor, a GPR17 antagonist, has been shown to inhibit GPR17 signaling [25, 32, 33], and reduce pulmonary fibrosis by inhibiting GPR17-mediated inflammation in mice [25]. The gene discussed is GPR17; the disease is pulmonary fibrosis.